CRISPR Therapeutics
CRSP · US
CRISPR Therapeutics is held by 2 of the 24 tracked investors in their latest 13F filings. The largest position is ARK Investment Management's at $516M, 3.35% of that portfolio. Versus the prior quarter, 0 added, 2 trimmed and 0 bought new.
Big investors holding this stock
Latest 13F of the 24 tracked investors. Common shares only.
| Investor | Value ($) | vs prior quarter |
|---|---|---|
| ARK Investment Management weight 3.35% · Q2 2026 |
516M | ▼ 16% |
| Norges Bank weight 0.00% · Q2 2026 |
14.8M | ▼ 45% |
Holding history
13F · shares at each quarter-end| Investor | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 |
|---|---|---|---|---|---|---|---|---|
| ARK | ||||||||
| Norway NBIM | ||||||||
| Baillie Gifford | · | · | · | · | · | · | · |
Bar height = shares of CRISPR Therapeutics relative to that investor's own peak in these quarters (split-adjusted); · = filed but did not hold; blank = no filing kept.
Questions
Which big investors own CRISPR Therapeutics?
ARK Investment Management ($516M), Norges Bank ($14.8M), per their latest 13F filings.
Does Warren Buffett own CRISPR Therapeutics?
Berkshire Hathaway did not report it in its latest 13F.
Does Korea's National Pension Service own CRISPR Therapeutics?
Not in its latest 13F.
Restated and computed from SEC (13F, 13D/G, Form 4) and DART filings and NPS public data. Filings describe a past date and may differ from current holdings (13F: quarter end, up to 45 days later). Not investment advice.
Sources: SEC EDGAR, DART, data.go.kr (NPS), OpenFIGI. See Methodology for how figures are computed.